Holmgaard et al. evaluated the combination of CTLA-4 blockade and IDO inhibition in the B16 melanoma mouse model, and data suggested that IDO inhibition can be employed to boost the effectiveness of immunotherapies in melanoma patients by augmenting T cell response. The gene discussed is CTLA4; the disease is melanoma.